Top US FDA Drug Policy Leader Leaving For White House Detail
Executive Summary
Grail Sipes, CDER deputy center director for regulatory policy, will move to the Executive Office of the President next month.
You may also be interested in...
Elizabeth Jungman: Interpreter Of The FDA’s Policy Crystal Ball
The Center for Drug Evaluation and Research’s policy guru must think about the future, along with the present, in her position as director of the Office of Regulatory Policy.
Biosimilars Forum’s New Executive Director Faces Down Challenge Of Interchangeability Confusion
Juliana Reed, who just moved from Pfizer to head the trade group, hopes scientific advances will eventually eliminate the need for the interchangeability designation, but for now the association is educating stakeholders in preparation for the 2023 launch of Humira biosimilars.
Califf Clears First Senate Hurdle, But FDA Abortion Pill Decision May Complicate Final Confirmation
Republican opposition to Califf over the agency’s recent move to relax its Mifeprex restrictions is ominous since in order be confirmed as FDA commissioner he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to the drug industry.